LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Lucid Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.10 (-21.05%)
Close on Oct 19, 2026
- Market cap
- $69.11M
- P/E (TTM)
- –
- Dividend yield
- –
Lucid Diagnostics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Market Cap | $76.70M | $229.23M |
| Enterprise Value | $43.30M | $194.73M |
| PS Ratio | 14.09 | 3.14 |
| PB Ratio | 7.02 | 3.19 |
| P/TBV Ratio | 7.09 | 4.69 |
Enterprise value
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| EV / Sales | 7.95 | 2.93 |
Income (trailing twelve months)
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Revenue | $5.45M | $102.39M |
| Operating Income | -$50.69M | -$4.31M |
| Pretax Income | -$52.26M | -$2.26M |
| Net Income | -$52.26M | -$6.57M |
| EBITDA | -$49.81M | -$1.98M |
| EPS (Diluted) | -$0.47 | -$0.07 |
Margins
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Operating Margin | -930.9% | -6.04% |
| Pretax Margin | -959.8% | -4.11% |
| Profit Margin | -959.8% | -10.5% |
| EBITDA Margin | -914.8% | -2.67% |
Returns
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -556.3% | -19.2% |
| Return on Assets (ROA) | -134.7% | -13.3% |
| Return on Capital Employed (ROCE) | -443.4% | -9.07% |
Growth
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 24.9% | 8.85% |
| Revenue Growth (3Y CAGR) | 132.0% | 7.08% |
Balance sheet
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $33.40M | $37.33M |
| Net Cash (Debt) | $33.40M | $3.92M |
| Net Cash Per Share | $0.16 | $0.28 |
| Equity (Book Value) | $10.93M | $57.36M |
| Book Value Per Share | $0.05 | $2.81 |
| Tangible Book Value | $10.82M | $10.71M |
| Working Capital | $9.11M | $54.64M |
Financial position
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Current Ratio | 1.33 | 2.50 |
| Quick Ratio | 1.25 | 1.54 |
| Interest Coverage | -2815.83 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Operating Cash Flow | -$46.87M | -$653.46K |
Efficiency
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Asset Turnover | 0.14 | 0.59 |
| Revenue Per Employee | $66.40K | $322.75K |
| Profits Per Employee | -$637.31K | -$52.11K |
| Employee Count | 82 | 197 |
Dividends and yields
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Earnings Yield | -68.1% | -6.92% |
Shares
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Shares Outstanding | 203,244,000 | 44,856,700 |
| Shares Change (YoY) | 103.5% | 3.35% |
| Shares Change (QoQ) | 15.7% | 0.27% |
| Float | 152,889,000 | 36,934,400 |
| Shares Held by Insiders | 24.8% | 10.6% |
| Shares Held by Institutions | 30.2% | 63.5% |
Scores
| Measure | Lucid Diagnostics | Industry median |
|---|---|---|
| Altman Z-Score | -13.47 | 1.95 |
| Piotroski F-Score | 4 | 5 |
| Beneish M-Score | 7.52 | -2.64 |
Calculated by StockData from Lucid Diagnostics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.